Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Exited and booked a loss before year-end following self-inflicted execution struggles, despite a leadership change and guidance reset.
— Ross Glotzbach
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Avantor, Inc.
Avantor provides mission-critical products and workflow services to life sciences and advanced technology industries globally, distributing laboratory chemicals, equipment, and bioprocessing consumables. The manager holds...
Life-sciences company Avantor detracted for the quarter.
Avantor was a close second. When we initiated...
More institutional theses from Longleaf Partners Global Fund
Rayonier ($RYN), representing 7.2% of the fund's portfolio, is a leading real estate investment trust specializing in timberland management, real estate development, and natural resource conservation across the United States and New Zealand. The manager maintains...
Regeneron Pharmaceuticals ($REGN), representing 4.7% of the fund's portfolio, is a leading biotechnology company that discovers, invents, and commercializes innovative medicines for serious diseases. The manager maintains...
Abbott Laboratories ($ABT) is a globally diversified healthcare company operating across medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. The manager established...